GlaxoSmithKline Pakistan Limited (PSX: GLAXO)
Pakistan
· Delayed Price · Currency is PKR 316.70
0.00 (0.00%)
At close: Nov 14, 2024
GlaxoSmithKline Pakistan Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 56,233 | 49,661 | 41,842 | 36,661 | 35,090 | 36,582 | Upgrade
|
| Revenue Growth (YoY) | 15.29% | 18.69% | 14.13% | 4.48% | -4.08% | 7.57% | Upgrade
|
| Cost of Revenue | 45,899 | 46,245 | 34,505 | 26,787 | 27,351 | 28,873 | Upgrade
|
| Gross Profit | 10,334 | 3,416 | 7,336 | 9,874 | 7,739 | 7,708 | Upgrade
|
| Selling, General & Admin | 6,225 | 6,528 | 5,139 | 3,857 | 4,064 | 4,308 | Upgrade
|
| Other Operating Expenses | -3,131 | -5,077 | -2,871 | -856 | -1,234 | -1,410 | Upgrade
|
| Operating Expenses | 3,094 | 1,451 | 2,268 | 3,001 | 2,830 | 2,898 | Upgrade
|
| Operating Income | 7,240 | 1,965 | 5,068 | 6,873 | 4,909 | 4,811 | Upgrade
|
| Interest Expense | - | -6.52 | -5.37 | -5.43 | -6.5 | -93.88 | Upgrade
|
| Interest & Investment Income | 439.82 | 277.02 | 829.54 | 374.94 | 235.53 | 137.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 68.24 | 68.24 | -703.51 | -156.49 | -75.86 | -191.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -56.48 | -56.48 | -7.37 | -2.52 | -1.75 | -4.71 | Upgrade
|
| EBT Excluding Unusual Items | 7,692 | 2,247 | 5,182 | 7,084 | 5,061 | 4,658 | Upgrade
|
| Merger & Restructuring Charges | -215.25 | -215.25 | -146.51 | -321.57 | -158.17 | -68.36 | Upgrade
|
| Gain (Loss) on Sale of Assets | 52.69 | 82.76 | 124.62 | 633.9 | 17.21 | 44.1 | Upgrade
|
| Asset Writedown | -6.01 | -6.01 | -54.02 | -15.54 | -80.81 | -40.33 | Upgrade
|
| Other Unusual Items | - | 68.56 | - | 43.88 | 63.87 | - | Upgrade
|
| Pretax Income | 7,523 | 2,177 | 5,106 | 7,424 | 4,903 | 4,600 | Upgrade
|
| Income Tax Expense | 3,017 | 1,643 | 2,643 | 2,070 | 1,527 | 1,559 | Upgrade
|
| Earnings From Continuing Operations | 4,507 | 533.95 | 2,463 | 5,354 | 3,375 | 3,041 | Upgrade
|
| Net Income | 4,507 | 533.95 | 2,463 | 5,354 | 3,375 | 3,041 | Upgrade
|
| Net Income to Common | 4,507 | 533.95 | 2,463 | 5,354 | 3,375 | 3,041 | Upgrade
|
| Net Income Growth | 248.99% | -78.32% | -54.00% | 58.64% | 10.99% | -6.66% | Upgrade
|
| Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade
|
| Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade
|
| EPS (Basic) | 14.15 | 1.68 | 7.73 | 16.81 | 10.60 | 9.55 | Upgrade
|
| EPS (Diluted) | 14.15 | 1.68 | 7.73 | 16.81 | 10.60 | 9.55 | Upgrade
|
| EPS Growth | 248.99% | -78.32% | -54.00% | 58.64% | 10.99% | -6.66% | Upgrade
|
| Free Cash Flow | 4,288 | -54.23 | -4,694 | 3,683 | 4,644 | 1,223 | Upgrade
|
| Free Cash Flow Per Share | 13.46 | -0.17 | -14.74 | 11.57 | 14.58 | 3.84 | Upgrade
|
| Dividend Per Share | - | - | - | 7.000 | 6.500 | 6.000 | Upgrade
|
| Dividend Growth | - | - | - | 7.69% | 8.33% | -14.29% | Upgrade
|
| Gross Margin | 18.38% | 6.88% | 17.53% | 26.93% | 22.05% | 21.07% | Upgrade
|
| Operating Margin | 12.88% | 3.96% | 12.11% | 18.75% | 13.99% | 13.15% | Upgrade
|
| Profit Margin | 8.01% | 1.08% | 5.89% | 14.61% | 9.62% | 8.31% | Upgrade
|
| Free Cash Flow Margin | 7.62% | -0.11% | -11.22% | 10.05% | 13.23% | 3.34% | Upgrade
|
| EBITDA | 8,314 | 2,881 | 5,910 | 7,634 | 5,658 | 5,606 | Upgrade
|
| EBITDA Margin | 14.78% | 5.80% | 14.12% | 20.82% | 16.12% | 15.33% | Upgrade
|
| D&A For EBITDA | 1,073 | 916.48 | 841.69 | 760.47 | 748.68 | 795.59 | Upgrade
|
| EBIT | 7,240 | 1,965 | 5,068 | 6,873 | 4,909 | 4,811 | Upgrade
|
| EBIT Margin | 12.88% | 3.96% | 12.11% | 18.75% | 13.99% | 13.15% | Upgrade
|
| Effective Tax Rate | 40.10% | 75.48% | 51.76% | 27.88% | 31.16% | 33.89% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.